Noy Ariela
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Curr Opin Oncol. 2006 Sep;18(5):449-55. doi: 10.1097/01.cco.0000239883.23839.ac.
Despite the control of HIV infection in industrialized nations, individuals infected with HIV remain at increased risk of malignancies. Lymphoma is the most common HIV-associated malignancy in these countries. This review summarizes progress from January 2005 to March 2006.
Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy. The majority of work has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising, and rituximab an area of investigation. The latter improves complete response rates, but is associated with an increased incidence of infections. Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.
The outcome for individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into the pathophysiology and treatment advance.
尽管工业化国家对HIV感染进行了控制，但感染HIV的个体患恶性肿瘤的风险仍然增加。在这些国家，淋巴瘤是最常见的与HIV相关的恶性肿瘤。本综述总结了2005年1月至2006年3月期间的进展。
研究人员继续证明，即使在高效抗逆转录病毒治疗时代，与HIV相关的非霍奇金淋巴瘤仍然是一个重大问题。大部分工作集中在弥漫性大B细胞淋巴瘤上，输注疗法仍然很有前景，利妥昔单抗是一个研究领域。后者提高了完全缓解率，但与感染发生率增加有关。对与HIV相关的非霍奇金淋巴瘤和霍奇金病的范围有了生物学见解，包括对病毒合并感染的进一步研究。
随着对病理生理学和治疗的认识不断提高，感染HIV并发展为非霍奇金淋巴瘤和霍奇金病的个体的预后持续改善。
